| Literature DB >> 34287292 |
Rafael Franco1,2, Berta Casanovas1, Jordi Camps1, Gemma Navarro2,3, Eva Martínez-Pinilla4,5,6.
Abstract
Although antioxidants can act locally to react with an oxidant, oral administration of "antioxidants" is quite useless in treating oxidative stress in tissues. Furthermore, it does not make sense to consider a vitamin as an antioxidant, but vitamin B3 leads to the in vivo formation of compounds that are essential for reducing this stress. A rigorous treatment of the subject indicates that to deal with oxidative stress, the most direct approach is to enhance the innate antioxidant mechanisms. The question is whether this is possible through daily activities. Diets can contain the necessary components for these mechanisms or may induce the expression of the genes involved in them. Another possibility is that pro-oxidant molecules in food increase the sensitivity and power of the detoxification pathways. This option is based on well-known DNA repair mechanisms after exposure to radiation (even from the Sun), or strong evidence of induction of antioxidant capacity after exposure to powerful pro-oxidants such as H2O2. More experimental work is required to test whether some molecules in food can increase the expression of antioxidant enzymes and/or improve antioxidant mechanisms. Identifying effective molecules to achieve such antioxidant power is critical to the food and nutraceutical industries. The potential of diet-based interventions to combat oxidative stress must be viewed from a new perspective.Entities:
Keywords: UV radiation; antioxidant; diet; hormesis; innate mechanisms; oxidative stress; redox
Mesh:
Substances:
Year: 2021 PMID: 34287292 PMCID: PMC8929025 DOI: 10.3390/cimb43020047
Source DB: PubMed Journal: Curr Issues Mol Biol ISSN: 1467-3037 Impact factor: 2.976
List of genes for the dose of 0.56 Gy that are common in both lists of the two administration regimes for this dose, acute or low dose.
| Gene Symbol | Gene Title | Acute logFC | Low logFC |
|---|---|---|---|
|
| Apoptosis-enhancing nuclease | 3.321 | 3.210 |
|
| TRIO and F-actin binding protein | 2.793 | 1.197 |
|
| Ferredoxin reductase | 2.774 | 2.637 |
|
| Damage-specific DNA binding protein 2, 48kDa | 2.071 | 1.901 |
|
| Pregnancy-associated plasma protein A, Pappalysin 1 | 1.882 | 2.502 |
|
| CD70 molecule | 1.827 | 1.646 |
|
| BCL2-associated X protein | 1.698 | 1.592 |
|
| Von Willebrand factor C and EGF domains | 1.660 | 1.528 |
|
| E2F transcription factor 7 | 1.596 | 1.364 |
|
| Actin, alpha 2, smooth muscle, aorta | 1.531 | 1.293 |
|
| Ribosomal protein S27-like | 1.527 | 1.329 |
|
| Tumor necrosis factor (ligand) superfamily, member 4 | 1.524 | 1.508 |
|
| Cyclin G1 | 1.463 | 1.304 |
|
| Tumor necrosis factor receptor superfamily, member 10b | 1.455 | 1.381 |
|
| Cyclin-dependent kinase inhibitor 1A (p21, Cip1) | 1.197 | 1.066 |
|
| BCL2 binding component 3 | 1.193 | 0.923 |
|
| Olfactory receptor, family 52, subfamily N, member 4 | 1.184 | 1.369 |
|
| Glutaminase 2 (liver, mitochondrial) | 1.172 | 1.117 |
|
| Retinol binding protein 4, plasma | 1.169 | 1.226 |
|
| Polymerase (DNA directed), eta | 1.137 | 0.821 |
|
| Tumor necrosis factor (ligand) superfamily, member 9 | 1.131 | 0.656 |
|
| Phosphohistidine phosphatase 1 | 1.123 | 0.847 |
|
| Killin, p53-regulated DNA replication inhibitor | 0.993 | 0.902 |
|
| Xeroderma pigmentosum, complementation group C | 0.966 | 0.957 |
|
| Sestrin 1 | 0.959 | 0.795 |
|
| Tumor necrosis factor (ligand) superfamily, member 8 | 0.925 | 1.063 |
|
| Cystatin SA | 0.924 | 1.067 |
|
| Growth differentiation factor 15 | 0.832 | 1.153 |
|
| Alkaline ceramidase 2 | 0.742 | 0.966 |
|
| Potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4 | 0.710 | 0.688 |
|
| Protein phosphatase, Mg2+/Mn2+ dependent, 1D | 0.692 | 0.707 |
|
| Ligase I, DNA, ATP-dependent | 0.631 | 0.567 |
|
| Transcription factor AP-4 (activating enhancer binding protein 4) | −0.694 | −1.163 |
|
| Chromosome 10 open reading frame 116 | −0.791 | −0.827 |
|
| Trace amine associated receptor 8 | −0.807 | −0.740 |
|
| Keratin associated protein 13-2 | −0.843 | −0.641 |
|
| LIM homeobox transcription factor 1, beta | −0.964 | −0.909 |
|
| Docking protein 5 | −0.976 | −1.534 |
|
| Nuclear receptor subfamily 1, group I, member 3 | −1.243 | −0.890 |
|
| Ankyrin repeat domain 34B | −1.248 | −1.538 |
|
| Secretin | −1.318 | −1.311 |
|
| Leiomodin 2 (cardiac) | −1.639 | −1.845 |
|
| Relaxin/insulin-like family peptide receptor 2 | −2.191 | −1.529 |
FC: Fold Change.
List of genes for the dose of 4.45 Gy that are common in both lists of the two administration regimes for this dose, acute or low dose.
| Gene Symbol | Gene Title | Acute logFC | Low logFC |
|---|---|---|---|
|
| Apolipoprotein B mRNA editing enzyme. catalytic polypeptide-like 3H | 4.746 | 3.957 |
|
| Von Willebrand factor C and EGF domains | 4.577 | 3.579 |
|
| Ferredoxin reductase | 4.505 | 3.961 |
|
| E2F transcription factor 7 | 4.108 | 3.581 |
|
| Apoptosis enhancing nuclease | 4.001 | 4.155 |
|
| Tumor necrosis factor (ligand) superfamily. member 4 | 3.701 | 2.914 |
|
| Pregnancy-associated plasma protein A. pappalysin 1 | 3.602 | 3.379 |
|
| Pleckstrin homology-like domain. family A. member 3 | 3.314 | 2.830 |
|
| Netrin 1 | 3.204 | 2.227 |
|
| Damage-specific DNA binding protein 2. 48kDa | 3.025 | 2.900 |
|
| CD70 molecule | 2.978 | 2.895 |
|
| Proliferating cell nuclear antigen | 2.895 | 2.787 |
|
| Growth differentiation factor 15 | 2.872 | 2.751 |
|
| Transmembrane protease. serine 7 | 2.777 | 2.194 |
|
| Cyclin-dependent kinase inhibitor 1A (p21. Cip1) | 2.619 | 2.297 |
|
| Actin. alpha 2. smooth muscle. aorta | 2.400 | 1.548 |
|
| Cyclin G1 | 2.390 | 1.865 |
|
| Tachykinin 3 | 2.367 | 1.459 |
|
| BCL2 binding component 3 | 2.133 | 1.867 |
|
| Polymerase (DNA directed). eta | 2.101 | 1.632 |
|
| BCL2-associated X protein | 2.074 | 2.134 |
|
| Glutamate receptor. ionotropic. N-methyl-D-aspartate 3B | 2.069 | 1.856 |
|
| Guanine nucleotide binding protein (G protein). alpha transducing activity polypeptide 2 | 2.056 | 2.409 |
|
| Phosphohistidine phosphatase 1 | 2.037 | 1.731 |
|
| Tumor necrosis factor (ligand) superfamily. member 9 | 2.028 | 2.195 |
|
| Fc receptor. IgA. IgM. high affinity | 1.842 | 1.704 |
|
| Laminin. gamma 3 | 1.774 | 1.444 |
|
| Sestrin 1 | 1.751 | 1.538 |
|
| Guanine nucleotide binding protein (G protein). gamma 4 | 1.728 | 1.802 |
|
| Polymeric immunoglobulin receptor | 1.639 | 2.238 |
|
| Alkaline ceramidase 2 | 1.628 | 1.424 |
|
| Tumor necrosis factor receptor superfamily. member 10b | 1.599 | 1.905 |
|
| G protein-coupled receptor 172B | 1.574 | 0.966 |
|
| Protein phosphatase. Mg2+/Mn2+ dependent. 1D | 1.566 | 1.310 |
|
| Tumor necrosis factor (ligand) superfamily. member 8 | 1.559 | 1.449 |
|
| Thymidylate synthetase | 1.491 | 1.579 |
|
| Lamin A/C | 1.438 | 1.780 |
|
| Immediate early response 5 | 1.417 | 1.237 |
|
| Olfactory receptor. family 52. subfamily N. member 4 | 1.388 | 1.965 |
|
| Mannosyl (beta-1.4-)-glycoprotein beta-1.4-N-acetylglucosaminyltransferase | 1.358 | 0.998 |
|
| Dihydrodiol dehydrogenase (dimeric) | 1.291 | 1.124 |
|
| Ligase I. DNA. ATP-dependent | 1.235 | 0.885 |
|
| Apolipoprotein B mRNA editing enzyme. catalytic polypeptide-like 3C | 1.163 | 1.144 |
|
| Potassium intermediate/small conductance calcium-activated channel. subfamily N. member 4 | 1.148 | 0.913 |
|
| DNA-damage regulated autophagy modulator 1 | 1.141 | 0.973 |
|
| C-mer proto-oncogene tyrosine kinase | 1.126 | 1.101 |
|
| Mitogen-activated protein kinase kinase kinase kinase 4 | 1.052 | 1.003 |
|
| Rho guanine nucleotide exchange factor (GEF) 3 | 1.052 | 1.090 |
|
| Coagulation factor V (proaccelerin. labile factor) | 1.049 | 1.150 |
|
| Ral guanine nucleotide dissociation stimulator-like 1 | 1.027 | 1.078 |
|
| Protein tyrosine phosphatase type IVA. member 1 | 1.006 | 0.883 |
|
| Protein kinase. AMP-activated. beta 1 non-catalytic subunit | 1.002 | 0.872 |
|
| Actin binding LIM protein family. member 2 | −0.929 | −0.967 |
|
| Protein phosphatase 2. regulatory subunit A. beta | −1.091 | −0.900 |
|
| Oxysterol binding protein-like 10 | −1.225 | −0.798 |
|
| Transcription factor AP-4 (activating enhancer binding protein 4) | −1.309 | −1.188 |
|
| Coronin. actin binding protein. 2B | −1.712 | −1.996 |
|
| Fc receptor-like 2 | −1.925 | −1.498 |
|
| CD160 molecule | −2.519 | −1.765 |
FC: Fold Change.
Figure 1Flow chart illustrating the benefits from a prior exposure to a seemingly noxious agent. Exposure to radioactivity, UV light from the Sun, H2O2 or some foods or chemicals present in foods (a) would increase the levels and/or the activities of antioxidant enzymes, thus improving the innate mechanisms of detoxification (b) that cope with the oxidative stress generated by a subsequent re-exposure to the same stressor, by exposure to a different stressor or by the regular exposure to a stressor (c).